Back to Rare Disease
This trial is complete. It is no longer accepting participants.

NCT00004795

NCT00004795
Completed Phase 3

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with systemic lupus erythematosus (lupus) based on recognised medical guidelines
  • Your lupus is considered mild to moderate in severity
  • You are taking prednisone (or a similar steroid medication) at a dose between 10 and 30 mg per day — not on an every-other-day schedule
  • Either: you tried to reduce your steroid dose in the last 12 months but were unable to, and your dose has been stable for at least 6 weeks before joining — OR: you have not tried to reduce your dose in the last 12 months, and your dose has been stable for at least 3 months before joining

Who may not be able to join:

  • You have previously taken part in a double-blind study of a supplement called DHEA at Stanford University
  • You are currently taking medications that suppress the immune system
  • You are currently taking part in another clinical study
  • You have taken any experimental medication within the past 30 days (or longer, depending on the medication)
  • You have received certain treatments — including hormones, immune system medications, or chemotherapy drugs — within the past 3 months (confirm with trial site for full list)
  • Your dose of anti-inflammatory drugs or a medication called hydroxychloroquine has changed within the past month
  • You have a known allergy or sensitivity to DHEA or any of its ingredients, including cornstarch, lactose, or magnesium stearate
  • You have a condition that would make it difficult for you to follow the study requirements reliably
  • You have a history of breast cancer or cancer of the reproductive organs
  • You are pregnant (a negative pregnancy test within 2 weeks before joining is required)
  • You are able to become pregnant but are not using a reliable form of contraception
  • You are taking a contraceptive pill that contains oestrogen

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
National Center for Research Resources (NCRR)
Registry
clinicaltrials_gov
Start date
1 August 1994

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov